Vancouver, BC (PRWEB) September 14, 2004

Dave Kalenuik, President and Director of Larrea Biosciences Corp. (OTCBB – LRRA) announces that the Company has entered into an agreement to acquire LarreaRx Inc., a private Wyoming company. Under the terms of the agreement, the Company will purchase 100% of the issued and outstanding shares of LarreaRx by issuing one share for every 5.5 shares of LarreaRx.

The Company also announces that it has amended the terms of its previously announced agreement to acquire Global Botanics International, Inc. (GBI). Both the Company and SBI have agreed to strike the redemption clause of the contract, whereby the Company has the option of purchasing back the shares issued to GBI within a two-year period. This is the only change that has been made to the agreement, and it remains otherwise fully valid and enforceable.

The statements in the press release that relate to the company’s expectations with regard to the future impact on the company’s results from acquisitions or actions in development are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995. The statements in this document may also contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company’s actual results may differ materially from expected results.

# # #

Find More Acquire Press Releases